The Food and Drug Administration has approved a new medication, Merck’s Lipfendra, as a convenient treatment for individuals with persistent high cholesterol. This approval marks a significant step for patients who are at elevated risk for cardiovascular issues and heart attacks.
Lipfendra is designed to be taken daily, providing an alternative to existing cholesterol-lowering injections. Its approval is expected to simplify the management of high cholesterol for many patients.
Leave a Reply